Company-wide revenue
Reported revenue in 2021 ¥756.23B Reported revenue in 2025 ¥825.38B
- growth amount
- +¥69.15B
- growth annualized
- +2.2%
- growth total
- +9.1%
Japanese company profile · 4523
Eisai Co., Ltd.
In its FY2025 public filing, Eisai Co., Ltd. reports Japan, The Americas, China, EMEA, and 1 other reported businesses. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: エーザイ株式会社
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
Eisai Co., Ltd.'s largest reported business by revenue in FY2025 was The Americas.
The business with the highest reported segment profit in FY2025 was The Americas.
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Revenue from external customers | Revenue share | Segment profit (loss) |
|---|---|---|---|
| The Americas | ¥300.44B ↗ | — | ¥174.38B ↗ |
| Japan | ¥229.24B ↗ | — | ¥72.98B ↗ |
| China | ¥130.75B ↗ | — | ¥59.31B ↗ |
| Business label unavailable in English | ¥81.53B ↗ | — | ¥30.41B ↗ |
| East Asia and the Global South | ¥68.82B ↗ | — | ¥30.25B ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Japan
- 日本
- The Americas
- アメリカス
- China
- 中国
- Business label unavailable in English
- EMEA
- East Asia and the Global South
- イーストアジア・グローバルサウス
- Asia and Latin America
- アジア・ラテンアメリカ
- Over-the-counter Medicines and Related Products
- 一般用医薬品等
- Revenue from external customers
- 外部顧客売上
- Segment profit (loss)
- セグメント利益（損失）
Original Japanese label
- Japan
- 日本
- The Americas
- アメリカス
- China
- 中国
- Business label unavailable in English
- EMEA
- East Asia and the Global South
- イーストアジア・グローバルサウス
- Asia and Latin America
- アジア・ラテンアメリカ
- Over-the-counter Medicines and Related Products
- 一般用医薬品等
- Revenue from external customers
- 外部顧客売上
- Segment profit (loss)
- セグメント利益（損失）
What is growing?
What is growing?
Business revenue growth
The Americas
Reported revenue in 2021 ¥172.02B Reported revenue in 2025 ¥300.44B
- growth amount
- +¥128.42B
- growth annualized
- +15.0%
- growth total
- +74.7%
View original filing
China
Reported revenue in 2021 ¥106.42B Reported revenue in 2025 ¥130.75B
- growth amount
- +¥24.32B
- growth annualized
- +5.3%
- growth total
- +22.9%
View original filing
Business label unavailable in English
Reported revenue in 2021 ¥59.34B Reported revenue in 2025 ¥81.53B
- growth amount
- +¥22.19B
- growth annualized
- +8.3%
- growth total
- +37.4%
View original filing
Japan
Reported profit margin in 2022 +31.5%
Reported profit margin in 2025 +31.8%
- growth margin points
- +0.4
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YB05
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.